Close
Digital Health & Ai Innovation summit 2026
APE 2026

NICE announces launch of a new database to inform the prioritisation of European cancer research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Amsino, ampiezza Join Hands for Pre-Filled...

Amsino International, Inc., which is a global manufacturer when...

W.L. Gore Sets Foot in Left...

W.L. Gore & Associates, the global materials science company,...

AHA Wins a Temporary Block on...

A federal judge in Maine has gone on to...

The National Institute for Health and Clinical Excellence has launched a new database that will help with the identification and prioritisation of future cancer research across Europe.

The Database of Cancer Uncertainties has been developed through the Coordination of Cancer Clinical Practice Guidelines in Europe initiative. CoCanCPG is a consortium of 16 institutional partners from 11 countries and is funded by the European Commission.

Uncertainties around the evidence base used in guideline development are common, indeed, it is rare that all aspects of the management of a condition are supported by high-quality research evidence. In some circumstances, the research has not been done and even where it has been done it may be methodologically flawed or inconclusive.

The cancer uncertainties database will provide a tool to bring these uncertainties together and link into other initiatives such as the UK’s Database of Uncertainties about the Effects of Treatments – DUETs. The uncertainties will be prioritised with input from clinicians, patients, funders and researchers. The prioritised uncertainties can then be promoted to research funders and researchers across the EU. Tracking mechanisms will be developed to avoid duplication of effort and highlight relevant clinical trials that patients can participate in. The co-ordination will help to ensure that the available research funds are spent against identified priorities.

Latest stories

Related stories

Amsino, ampiezza Join Hands for Pre-Filled Flush Syringes

Amsino International, Inc., which is a global manufacturer when...

W.L. Gore Sets Foot in Left Atrial Appendage Occlusion Tech

W.L. Gore & Associates, the global materials science company,...

Maimonides Health Merger with NYC Health + Hospitals Soon

Maimonides Health, which is Brooklyn, New York-based, is going ahead...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »